BiotechTubeBiotechTube
Home/Otsuka Holdings/Taro Iwamoto
TI

Taro Iwamoto

Representative Director, Executive Vice President and CFO

Otsuka Holdings

Therapeutic Areas

PsychiatryNeurologyOncologyNephrologyCardiovascular

Otsuka Holdings Pipeline

DrugIndicationPhase
Abilify (aripiprazole)Schizophrenia, Bipolar DisorderCommercial
Rexulti (brexpiprazole)Major Depressive Disorder, SchizophreniaCommercial
Abilify MaintenaSchizophrenia, Bipolar I DisorderCommercial
OPC-64005Alzheimer's Disease PsychosisPhase 3
CentanafadineADHDPhase 3
OPC-34712Major Depressive DisorderPhase 2
Nuedexta (AVP-923)Pseudobulbar AffectCommercial
Jynarque/Jinarc (tolvaptan)ADPKDCommercial

Leadership Team at Otsuka Holdings

MI
Makoto Inoue
Representative Director, President and CEO
IO
Ichiro Otsuka
Chairman of the Board
WC
William Carson
Chief Medical Officer, Otsuka Pharmaceutical Development & Commercialization
KN
Kabir Nath
CEO, Otsuka America Pharmaceutical
View full Otsuka Holdings profile